Last month, Gilead Sciences reported that it had met its goals in two late-stage hepatitis C virus (HCV) drug trials. The trials, called Fission and Neutrino, incorporated the experimental HCV drug sofosbuvir as part of a combination 12-week therapy in previously untreated patients with chronic HCV.

Inspiration Biopharmaceuticals, Inc., announced in early February that it had reached a deal to sell its developmental therapy IB1001 at auction to Cangene, a Winnipeg, Canada-based pharmaceutical company.

Baxter International, Inc., recently announced its submission of a biologics license application (BLA) supplement to the US Food and Drug Administration (FDA) for the approval of prophylactic treatment of FEIBA NF in patients with hemophilia A or B and inhibitors.

On March 12, 2013 Biogen Idec announced that the company submitted a Biologics License Application (BLA) to the FDA for the marketing approval of recombinant factor VIII Fc fusion protein (rFVIIIFc) for the treatment of hemophilia A.

Last month CSL Behring announced that the US Food and Drug Administration (FDA) has approved an expansion of the indication for Corifact®, a human plasma-derived factor XIII (FXIII) concentrate, to include the peri-operative management of surgical bleeding in adult and pediatric patients with congenital FXIII deficiency.

In mid-April, Achillion Pharmaceuticals, Inc., initiated an international Phase 2 clinical trial evaluating its new drug ACH-3102, in combination with ribavirin and another one of its drugs, sovaprevir (ACH-1625), for the treatment of patients with chronic hepatitis C virus (HCV) infections, genotype 1.